Key TakeawaysArrowhead Pharmaceuticals reported a Phase-3 study of its medicine for a rare genetic disorder met all its primary endpoints and key secondary endpoints.The drug, called Plozasiran, helped patients with familial chylomicronemia syndrome (FCS), which has no currently approved treatment.Arrowhead said it plans to file a new drug application with the Food and Drug Administration (FDA) this year. Shares of Arrowhead Pharmaceuticals (ARWR) gained Tuesday after the biotech firm announced positive res ...